#EULAR2019 session ‘Getting A Grip on The Comorbidities in Gout’ focused on the complex and variable disease profile patients experience and clinicians treat. Do #gout co-morbidities occur in patterns? Dr Ed Roddy discusses. Abstract SP0061 @RheumNow https://t.co/EHoNdP7iMo

Baracitinib affects JAK2 more than Tofacitinib. Difference can be seen with lower Hb & higher platelets #EULAR2019 https://t.co/BfzuyZI8f9

JAKi also helps reduce bone loss #EULAR2019 https://t.co/8JOUp3aJWQ

This graph is a reminder that over time, the level of Inflammation in RA may reduce with lower symptoms. However, CUMULATIVE inflam leads to increasing damage & disability #EULAR2019 https://t.co/ujhODMOp4E

Look at the difference in patient reported outcome measures. Baracitinib vs Adalimumab #EULAR2019 https://t.co/xrQDdKIspV

Risk factors for #sarcopenia in #rheumatoid arthritis 👉🏼Male 👉🏼Old age 👉🏼Glucocorticoid 👉🏼Increased MMP3 👉🏼Increased HAQ #EULAR2019 THU0159 #muscle #RheumatoidArthritis https://t.co/Fn1SvCapqm

patients are lucky to have docs like @DrHillaryNorton sharing these #arthritis #breakthroughs #EULAR2019 https://t.co/nQg1WIFD4c

• Hillary Norton on Twitter: "Dr. van der Heijde presents results of dual ne…

Optimizing ➡️#weight ➡️sleep ➡️physical #health ➡️emotional health ➡️MTX use 👉🏼may improve persistent #fatigue beyond control of #rheumatoid inflammation via @Susanbartlett12 #EULAR2019 #obesity https://t.co/vuMNWazloo

TNF inhibitors vs JAK inhibitors: what’s the head-to-head study state of play? (**efficacy not safety, non-real life data of course) #EULAR2019 Gerd Burmester on ‘The wind of change in RA’ @RheumNow https://t.co/zK1wqskmLc

AE in SENCIS data. #EULAR2019 Ofev had higher discontinuation due to medication and higher GI associated illness in the trial. https://t.co/0E21Z4B8TU

MAXIMISE: rct of secukinumab on axial manifestations of PsA #EULAR2019 Positive as we would expect https://t.co/I1GfxlfWuX

Burmester on combining TNFi and JAK inhibitors in RA: “I have approached... even companies with both a TNF inhibitor and a JAK inhibitor. I have failed”. Wouldn’t it be interesting to see some data on this? #EULAR2019 @RheumNow

Solid tumors outcomes in patients with RA treated with #Abatacept - no increase in risk 5.2k in patients over 10years Dra. Teresa Simon #EULAR2019 https://t.co/BIA90SH7qc

I am also a big fan of BPs for their durability of treatment effect https://t.co/DKNYboSjdA

• Dr Irwin Lim on Twitter: "You speak sense. And I do what you do for steroi…

Gerd Burmester raising some interesting practical questions regarding the use of #biosimilars at #EULAR2019: How many drugs can a rheumatologist memorize? How much information material et.c can a rheumatologist store? How to avoid the ‘#nocebo’ effect when switching?